

APRIL

27-28
2017

10TH MEETING

OF THE EUROPEAN FORUM ON

ANTIPHOSPHOLIPID ANTIBODIES

FACULTY OF
MEDICINE
NANCY
FRANCE



APRIL | 27-28
2017

10TH MEETING
OF THE EUROPEAN FORUM ON

ANTIPHOSPHOLIPID ANTIBODIES

FACULTY OF MEDICINE
NANCY FRANCE

www.apsnancy.com

EDITORIAL

Dear Members of the Forum,

All our team is thrilled to welcome you to the *10th Meeting of the European Forum on Antiphospholipid Antibodies*.

This Forum meeting is the best place for the European clinicians and scientists involved in the field of APS to meet and strengthen current or future collaborations.

Furthermore, state of the art lectures as well as satellite symposiums are in the program.

Nancy is the capital of the artistic movement Art Nouveau that flourished in Nancy and across Europe from the late 19th century. Its influence is particularly visible in Nancy architecture. We will be delighted to invite you to a very special congress dinner which will take place in the Fine Arts Museum located in the Stanislas square inscribed on the UNESCO World Heritage List.

Sincerely yours,

Dr Jessie Risse,
Pr Stéphane Zuily
and Pr Denis Wahl
on behalf of the organizing committee

THURSDAY, APRIL 27

09.00 REGISTRATION AND WELCOME COFFEE

09.45 INTRODUCTION

M. Braun, Dean of Nancy Medical School
M. Claudon, CME President Nancy Academic Hospital
R. Cervera, General Coordinator
D. Wahl, S. Zuily

10.15 - 11.40 | NEW STUDIES : PRESENTATION AND DISCUSSION

Chairs : R. Cervera, D. Wahl

■ 10.20 - 10.35

Value of IgA anti β_2 -GPI measurement in SLE
A. Tincani, R. Kumar, L. Andreoli

■ 10.35 - 10.50

Circulating immune-complexes of IgG, IgA and IgM bound to β_2 -GPI and acute thrombotic events
D. Pérez, A. Serrano

■ 10.50 - 11.05

HIBISCUS: an international project as regards the effects of Hydroxychloroquine in preventing both thrombotic and obstetrical relapses
C. Belizna

■ 11.05 - 11.20

DUCSDATA: a Dutch Consortium Study on Diagnostics And Treatment of Antiphospholipid syndrome
M. Limper, R.T. Urbanus, H.G. Otten

■ 11.20 - 11.40

INSPIRE: the first Italian inception cohort of subjects positive for anti-phospholipid antibodies
V. Pengo, L. Andreoli, A. Banzato, C.B. Chighizola, E. Bison, R. Kumar, F. Pregnotato, F. Franceschini, M. O. Borghi, G. Morozzi, M. Lotzniker, A. Radice, A. Tincani, P.L. Meroni on behalf of FIRMA group

11.40 - 13.00 | ABSTRACTS PRESENTATION

Chairs : L. Andreoli, P. de Groot

■ 11.40 - 11.55

Increased prothrombin conversion causes elevated thrombin generation in APS patients with prior thrombosis
R. Kremers, S. Zuily, V. Regnault, D. Wahl, B. de Laat

■ 11.55 - 12.10

Thrombin activatable fibrinolysis inhibitor (TAFI) - a possible link between coagulation and complement activation in the APS
G. Grosso

■ 12.10 - 12.25

Role of platelet activation in a mouse model of APS
V. Proulle

■ 12.25 - 12.40

Lessons from the national antiphospholipid syndrome cohort: criteria and non-criteria manifestations
L. Stojanovich

■ 12.40 - 12.55

aPS/PT antibodies: a clue to predict intrauterine growth restriction and preeclampsia in APS patients
V. Canti

■ 12.50 - 13.00

Thrombotic manifestations in antiphospholipid antibody-related to virus infections
E. Esteve-Valverde, M. Bonet-Álvarez, N. Gil-Aliberas, G. López, R. Ferrer-Oliveras, J. Trapé, A. Baraldés-Farré, J. Alijotas-Reig

13.00 - 14.00 | LUNCH AND LATE BREAKING POSTER PRESENTATIONS

Refractory obstetrical antiphospholipid syndrome: features, treatment and outcome in a European multicentre retrospective study
A. Mekinian on behalf of the SNFMI and the European Forum on Antiphospholipid Antibodies

Non-conventional antiphospholipid antibodies in patients with clinical obstetrical APS: prevalence and pregnancies treatment efficacy

A. Mekinian, M.C. Bourrienne, L. Carbillon, A. Benbara, N. Abisor, S. Chollet-Martin, A. Tigaizin, F. Montestruc, O. Fain, P. Nicaise-Roland

Antibodies against S100A10 protein in antiphospholipid syndrome

V. Salle, J. Schmidt, A. Galmiche, M. Aubignat, C. Gourguechon, A. Dernoncourt, A. Smail, M.A. Delbarre, F. Pater, A. Brulé, Y.E. Herpe, P. Duhaut

14.00 - 14.30 | STATE OF THE ART LECTURE

The conformation of β_2 GPI and its diagnostic implications

B. de Laat

14.30 - 16.00 | SCIENTIFIC SESSION 1

NEW TESTS/NEW TECHNIQUES FOR ANTIPHOSPHOLIPID ASSAYS

Chairs: K. Devreese, B. de Laat

ABSTRACTS AND INVITED PRESENTATIONS

■ 14.30 - 14.55

New automated measurement technologies for aPL testing

K. Devreese

■ 14.55 - 15.05

A thrombin generation-based assay to distinguish anti- β_2 glycoprotein I and anti-prothrombin antibodies: paving the way to a better thrombotic risk assessment in patients with antiphospholipid syndrome

W. Chayouà et al.

■ 15.05 - 15.20

Recommendations from the ISTH-SSC for testing aPL with solid phase assays

K. Devreese

■ 15.20 - 15.30

Antiphospholipid antibody titer stability after repeated freeze-thaw cycle: Solid as a Rock

K. Maelegheer, M. Luypaert, K. Devreese

■ 15.30 - 15.40

APScdb: a database for efficient computing of antiphospholipid positivity profiles from laboratory records

M.D. Devignes, M. Smail-Tabbone, A. Hervé, S. Zuily, D. Wahl, J. Devignes

■ 15.40 - 15.50

Usefulness of the non-conventional antiphospholipid antibodies in the diagnostics of APS

E. Litvinova, L. Darnige, Y. Burnel, M.A. Dragon-Durey

■ 15.50 - 16.00

Anti-domain I- β_2 Glycoprotein I antibodies in antiphospholipid antibody carriers

M. Tonello, E. Mattia, T. Del Ross, M. Favaro, A. Calligaro, A. Hoxha, E. Bison, V. Pengo, A. Ruffatti

16.00 - 16.30 | COFFEE BREAK

16.30 - 18.00 | SCIENTIFIC SESSION 2

OBSTETRICAL APS

Chairs: A. Ruffatti, J.C. Gris, O. Morel

ABSTRACTS PRESENTATIONS

■ 16.30 - 16.45

A survey of the European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS)

E. Esteve-Valverde for the EUROAPS Study Group

■ 16.45 - 17.00

Prevalence of antiphospholipid antibodies in pregnant women at the time of preeclampsia detection

B. Grand, A. Avigliano, M. Gonzalez Alcántara, L. Voto

■ 17.00 - 17.15

Additional treatments combined with conventional therapies for high risk obstetric primary antiphospholipid syndrome: An international multicentre retrospective study

A. Ruffatti et al.

■ 17.15 - 17.30

Effect of adjusted doses of heparin and switch therapy on pregnancy outcome in primary antiphospholipid syndrome. A prospective cohort management study

A. Hoxha, M. Favaro, A. Calligaro, T. Del Ross, A.T. Ruffatti, C. Infantolino, M. Tonello, E. Mattia, A. Ruffatti

FORUM PROJECTS UPDATE

■ 17.30 - 17.45

The obstetric risk and the effect of treatment in women with low titer anti-phospholipid antibodies

C.B. Chighizola, F. Pregnolato, M.G. Raimondo, L. Trespidi, M. Gerosa, B. Acaia, M. Wally Ossola, P.L. Meroni

**18.00 - 19.00 | SATELLITE SYMPOSIUM:
NEW ANTICOAGULANT STRATEGIES FOR
THROMBOSIS PREVENTION**

Chairs : V. Eschwege, S. Zuily

■ 18.00 - 18.15

DOAC studies in VTE
S. Zuily

■ 18.15 - 18.30

Which lessons from DOAC studies could apply to APS?
A. Delluc

■ 18.30 - 18.45

AstroAPS (video presentation)
S. Woller

■ 18.45 - 19.00

Primary prophylaxis of thrombosis: new perspectives?
L. Arnaud

19:30 - 23:30 | CONGRESS DINNER

FRIDAY, APRIL 28

08.30 - 9.00 | STATE OF THE ART LECTURE

Pathophysiology of APS
P. de Groot

**09.15 - 10.15 | SCIENTIFIC SESSION 3
DOACs IN APS**

Chairs : H. Cohen, V. Pengo

■ 09.15 - 09.30

RAPS Study
H. Cohen

■ 09.30 - 9.45

TRAPS Trial
V. Pengo

■ 09.45 - 10.00

Review of literature data
S. Zuily

■ 10.00 - 10.10

Direct thrombin inhibitors in patients with antiphospholipid syndrome
M.A.Satybaldyeva, N.V.Seredavkina, L.N. Kashnikova, I.N. Gorskikh, E.L.Nasonov, T.M. Reshetnyak

■ 10.10 - 10.15

Future of DOACs in APS
D. Wahl

10.15 - 10.45 | COFFEE BREAK

**10.45 - 11.50 | SCIENTIFIC SESSION 4
NEW TARGETS / TREATMENTS**

Chairs : P.L. Meroni, V. Regnault

■ 10.45 - 11.05

TREM1: potential player in APS?
S. Gibot

■ 11.05 - 11.20

High risk laboratory APS Syndrome
J. Swadzba

■ 11.20 - 11.30

Rituximab in APS (excluding CAPS)
R. Cervera

■ 11.30 - 11.50

Complement inhibition and mTOR inhibition: perspectives
G. Canaud

11.50 - 12.20 | STATE OF THE ART LECTURE

Catastrophic antiphospholipid syndrome: Lessons from the "CAPS registry" and the "PRECISEADS project"
R. Cervera

12.30 - 13.30 | SATELLITE SYMPOSIUM INOVA UNMEET NEEDS IN APS: VALUE OF THE NEW ANTI- PHOSPHOLIPID ANTIBODY TESTING

Chair: D. Wahl

■ 12.30 - 12.50

β_2 Glycoprotein 1 Domain 1 in the assessment of thrombosis risk in APS

V. Pengo

■ 12.50 - 13.10

The detection of anti-PS/PT antibodies in routine

L. Bertolaccini

■ 13.10 - 13.30

Clinical utility for the Global APS Score (GAPSS)

S. Sciascia

13.30 - 14.15 | LUNCH AND POSTER VISIT

Endothelial dysfunction in antiphospholipid syndrome: myth or truth

N. Stanislavljevic

SLE: Quality of life in secondary antiphospholipid syndrome

G. Bogdanovic

Effects of Hydroxychloroquine for the prevention of miscarriages in obstetrical antiphospholipid syndrome

C. Belizna, C. Bertrand, C. Bertrand, L. Sentilhes

Arterial stiffness in APS and effects of treatment

C. Belizna, G. Desportes, A. Ghali, M. Hallab

Anti-factor-Xa-activity of selective and nonselective factor Xa inhibitors in patients with antiphospholipid syndrome and systemic lupus erythematosus

N.V. Seredavkina

Knowledge Management in Immunology with Content Curation

G.C. Faure, C. Andre-Botte, C. Kohler, D. Gerard, A.S. Lagneau, M. De Carvalho Bittencourt

Use of TNF- α blockers in aPL-positive women with recurrent infertility (refractory cases)

E. Esteve-Valverde, R. Ferrer-Oliveras, J. Alijotas-Reig

Laboratory and clinical characteristics of isolated Lupus Anticoagulants

E. Mattia, M. Tonello, T. Del Ross, A. Calligaro, M. Favaro, P. Terbinati, E. Campello, P. Simioni, A. Ruffatti

Catastrophic antiphospholipid syndrome (CAPS) in pregnancy: maternal and perinatal outcome in next pregnancies

B. Grand, G. Mainetti, A. Weinsziehr, M. Gonzalez Alcántara, L. Voto

Maternal and perinatal outcome in antiphospholipid syndrome (APS) with first line therapy (FLT) with low molecular weight heparin (LMWH) and low dose aspirin (LDA)

B. Grand, G. Mainetti, R. Zarate, M. Gonzalez Alcántara, L. Voto

14.30 - 16.00 | SCIENTIFIC SESSION 5 NEUROPSYCHIATRIC APS

Chairs: E. Hachulla, S. Sciascia

STATE OF THE ART LECTURES

■ 14.30 - 15.00

Evidences of neuropsychiatric risk and of infra-clinic brain alterations in APS women with no thrombotic history

J.C. Gris

■ 15.00 - 15.30

Cognitive manifestations of APS

C. Yelnik

ABSTRACT PRESENTATIONS

■ 15.30 - 15.40

Possible relationship between valvular lesions and neurological manifestations in patients with primary and secondary antiphospholipid syndrome

A. Djokovic

■ 15.40 - 15.50

Antiphospholipid Antibodies as a Risk Marker of Embolic Events in Infective Endocarditis

J. Devignes, C. Selton-Suty, C.H. Maigrat, F. Goehringer, M.-L. Erpelding, F. Alla, C. Thivillier, O. Huttin, Y. Juillièrre, T. Doco-Lecompte, T. Lecompte

16.00 | CLOSING REMARKS

ORGANIZING COMMITTEE
@ NANCY ACADEMIC HOSPITAL / FACULTY OF MEDICINE

Vascular Medicine Division and Regional
 Competence Center for Rare Vascular and Auto-
 Immune Diseases
 Rue du Morvan, 54511 Vandoeuvre-Lès-Nancy
 Cedex, France

Dr J. Risse, Pr S. Zuily, Pr D. Wahl

- Haematology: Dr V. Eschwège, Dr J. Devignes
- Immunology: Dr E. André-Botté
- Internal Medicine: Dr M. Heymonet,
 Dr S. Mohamed, Dr F. Maurier, Pr R. Jaussaud
- Obstetrics: Dr C. Lamy, Pr O. Morel
- Cardiovascular Research Unit
 (Inserm UMR_S 1116): Dr V. Regnault
- Association des Chefs de Service Hospitaliers
 du CHRU de Nancy (partnership): Mme Vauthier
- Nancy Faculty of Medicine, Lorraine University:
 E. Schal (logistics), L. Philis (communication),
 L. Phialy (graphic design)

INTERNATIONAL STEERING COMMITTEE

Pr P. de Groot (The Netherlands), Pr P.L. Meroni
 (Italy), Pr V. Pengo (Italy), Pr A. Ruffatti (Italy),
 Pr M. Khamashta (UK), Pr Y. Shoenfeld (Israël),
 Pr A. Tincani (Italy), Pr J. Swadzba (Poland),
 Pr J. Musial (Poland), Pr R. Cervera (Spain),
 Pr D. Wahl (France)

FRENCH SCIENTIFIC COMMITTEE

Pr Z. Amoura (Paris), Pr L. Arnaud (Strasbourg),
 Dr C. Belizna (Angers), Pr Y. Benhamou (Rouen),
 Pr A. Bura-Rivière (Toulouse), Pr J. Constans
 (Bordeaux), Pr N. Costedoat-Chalumeau (Paris),
 Dr L. Darnige (Paris), Pr A. Delluc (Brest),
 Dr E. Demaistre (Dijon), Pr J.C. Gris (Nimes),
 Pr F. Guillemin (Nancy), Pr E. Hachulla (Lille),
 Dr P. Lacolley (Nancy), Pr M. Lambert (Lille),
 Pr T. Martin (Strasbourg), Pr G. Pernod (Grenoble),
 Pr I. Quééré (Montpellier),
 Pr D. Stephan (Strasbourg)



— SCIENTIFIC SUPPORT —

— INDUSTRY —



Bristol-Myers Squibb



Inova
 Diagnostics
 A Werfen Company

